SCHEMBL4955012

SCHEMBL4955012

COc1ccc(C2CCN(S(=O)(=O)CO[PH](=O)OCS(=O)(=O)N3CCC(c4ccc(OC)cc4)CC3)CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.50
USP5 P45974 1/20 0.47
THRB P10828 1/20 0.46
MMP3 P08254 1/20 0.45
ACLY P53396 1/20 0.44
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALDH1A1 P00352 4/20 0.40
PKM P14618 2/20 0.40
CCR6 P51684 1/20 0.40
NPC1 O15118 1/20 0.40
PKLR P30613 1/20 0.40
RAB9A P51151 1/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C19 P33261 1/20 0.40
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
CHRM2 P08172 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4955014 0.90 USP5 (0.48) DRD2USP5THRBMMP3ACLY
SCHEMBL1103992 0.79 HTT (0.57) DRD2USP5THRBACLYMAPT
SCHEMBL4959570 0.78 LMNA (0.59) DRD2THRBMAPTSMN1; SMN2ALDH1A1
SCHEMBL4955695 0.78 USP5 (0.52) DRD2USP5THRBMMP3ACLY
SCHEMBL2156514 0.77 DRD2 (0.48) DRD2USP5THRBMMP3ACLY
SCHEMBL2155443 0.75 DRD2 (0.49) DRD2USP5THRBMMP3ACLY
SCHEMBL2156510 0.73 DRD2 (0.47) DRD2USP5THRBMMP3ACLY
SCHEMBL5510215 0.72 DRD2 (0.52) DRD2USP5THRBMMP3ACLY
SCHEMBL294302 0.72 THRB (0.65) USP5THRBMAPTSMN1; SMN2ALDH1A1
SCHEMBL16493563 0.72 MMP3 (0.46) DRD2USP5MMP3MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828160-B1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS MERCK SERONO SA (CH) 2011-12-14 EP disclosed
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof MERCK SERONO SA (CH) 2008-08-14 US disclosed
EP-1828160-A1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS LABORATOIRES SERONO S.A. (CH) 2007-09-05 EP disclosed
WO-2006067114-A1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF LABORATOIRES SERONO S.A. (CH) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof GLS2, SRM, GLS DRD2 4576/4885USP5 1355/4885THRB 2589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.